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Mercury Levels in Mothers
I read with great interest the excellent arti-
cle by Mahaffey et al. (2004), which fur-
ther describes the characteristics of the
1,709 women from the National Health
and Nutrition Examination Survey
(NHANES) 1999–2000 who were sam-
pled for total and organic mercury levels in
blood. It adds valuable detail to the initial
report published last year (Schober et al.
2003). I would appreciate clarification on
one important point: in the “Discussion,”
the authors cited a new analysis which
indicates that the cord blood:maternal
blood ratio is not 1:1 as assumed by the
National Research Council (NRC) in
2000 (Committee on the Toxicological
Effects of Methylmercury 2000), but
rather 1.7:1. Using the same benchmark
dose lower limit and uncertainty factor
used by the NRC, Mahaffey et al. (2004)
calculated that blood total mercury levels
> 3.5 µg/L in mothers could be associated
with increased risk to the developing fetal
nervous system. I am very interested in the
details of this analysis and particularly in
understanding why the uncertainty factor
applied by the NRC to account in part for
toxicokinetic variability does not compen-
sate for uncertainty related to the cord
blood:maternal blood mercury ratio. This
is a critical concept because it has a dra-
matic impact on how many women may
carry mercury levels in excess of what is
believed to be safe for a fetus.
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Editors note: In accordance with journal
policy, Mahaffey et al. were asked whether they
wanted to respond to this letter, but they chose
not to do so.
U.S. PBDE Levels: Effects in Mice
I am pleased to submit this letter as a repre-
sentative of the American Chemistry Council
Brominated Flame Retardants Industry
Panel (BFRIP). The BFRIP is composed of
producers of brominated flame retardants;
member companies include Albemarle
Corporation, Ameribrom Inc., and Great
Lakes Chemical Corporation. 
In a recent study, Sjödin et al. (2004)
investigated polybrominated diphenyl ethers
(PBDEs) in human sera collected in the
United States between 1988 and 2002. The
authors concluded that such levels were
increasing over time and were higher than
those reported in Europe. Several points
regarding these conclusions require clarifica-
tion and are addressed below. 
Sjödin et al. (2004) used the term
“PBDEs”; however, the PBDEs analyzed in
sera were only the tetra to hepta congeners.
These congeners are commonly found in the
commercial pentaBDE product, which is
used in flexible polyurethane foam in uphol-
stery applications. The sole U.S. manufac-
turer of the pentaBDE product (Great Lakes
Chemical Corporation, West Lafayette, IN)
will voluntarily discontinue production by
the end of 2004. However, approximately
80% of the global production of PBDEs is
composed of the decabromodiphenyl
ether/oxide (DBDPO) commercial product,
which is used primarily in electrical and elec-
tronic components (typically television cabi-
net backs, connectors, and wire and cable
insulation) and to a minor extent in uphol-
stery textiles. DBDPO was not included in
the set of congeners analyzed by Sjödin et al.
(2004). Thus, the comments with respect to
time trends, if valid, apply only to tetra- to
heptaPBDE congeners and not the major
PBDE product in production and use,
DBDPO. 
Second, the results indicate that the
PBDEs, and BDE-47 in particular, for the
last two time intervals (1995–1999 and
2000–2002) appeared to level off. Of the
six isomers analyzed, only BDE-153
appeared to increase between 1995–1999
and 2000–2002. Thus, the most recent
data suggest that, in general, U.S. PBDE
serum levels for the lower congeners are
not continually increasing but have reached
a plateau. 
Third, the authors state that BDE-47
concentrations collected in similar time
frames and reported by other studies in milk
(83 or 130 ng/g lipid) and sera (0.63 ng/g
lipid, 1988) compare “favorably” with their
present sera results of 46 (1995–1999), 34
(2000–2002), and 5.4 (1985–1988) ng/g
lipid. These values appear dissimilar from
one another and appear to point out highly
variable, rather than similar, results. 
Finally, we question the validity of a com-
parison of U.S. to European PBDE levels. As
indicated by Sjödin et al. (2004), the ana-
lyzed sera were not collected in such a way as
to be representative of the general U.S. popu-
lation. The same is likely true with respect to
the blood and milk samples collected in
Sweden; these samples are unlikely to be rep-
resentative of the general European popula-
tion. Thus, based on this collection process,
one cannot reach reliable conclusions regard-
ing U.S. versus European levels. 
I would also like to correct information
reported regarding manufacture of poly-
brominated biphenyls (PBBs). Sjödin et al.
(2004) stated that the hexaBB product con-
tinued to be produced in Europe after the
Michigan incident in the 1970s in which it
was accidentally included in cattle feed.
After that incident, production of only the
decabromobiphenyl (decaBB) product, not
the hexaBB product, continued in Europe,
and that production ceased several years
ago. The decaBB product did not exhibit
the same toxicologic properties as the
hexaBB product.
Finally, Sjödin et al. (2004) stated that
“PBDEs cause neurodevelopmental effects in
mice …,” citing Eriksson et al. (2001, 2002)
and Viberg et al. (2002). Taylor et al. (2002)
were unable to reproduce these effects in rats,
whereas Viberg et al. (2004) reported similar
results in rats and mice. Perhaps these diverg-
ing results are related to the small sample size
and statistical design used by Eriksson et al.
(2001, 2002) and Viberg et al. (2004) that
grossly inflates the type 1 (i.e., false positive)
error rate. Eriksson et al. and Viberg et al.
both used mouse pups as the experimental
unit, whereas the litter is the more appropri-
ate measure [U.S. Environmental Protection
Agency (EPA) 2004; Organisation for
Economic Co-operation and Development
(OECD) 2003]. Litter effects are substantial,
and using more than one pup from a few lit-
ters, as reported by Eriksson et al. (2001,
2002) and Viberg et al. (2004), will con-
found treatment effects with litter effects
(Holson and Pearce 1992). Holson and
Pearce also stated that “within-litter variance
would likely become substantially lower with
age than that between litters.” This would
further increase the already sizeable effects of
litter and may account for the conclusions of
Eriksson et al. (2001, 2002) and Viberg et al.
(2004) that neurodevelopmental effects
increase with age.
The author is the manager of the American
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PBDEs: Sjödin’s Response
I appreciate Cleet’s response to our paper
concerning time trends of polybrominated
diphenyl ethers (PBDEs) and related com-
pounds in the U.S. population (Sjödin et al.
2004), and I appreciate the opportunity to
address his comments. 
Pentabromodiphenyl ether (pentaBDE),
along with the lower brominated congeners,
was the topic of our investigation (Sjödin
et al. (2004). Cleet’s statement emphasizing
that the current production of PBDEs is
solely in the form of decabromodiphenyl
ether belittles the fact that, in 2001, 95% of
the 7,500 metric tons of pentaBDE was pro-
duced and consumed in the United States
[Bromine Science and Environmental
Forum (BSEF) 2003]. The industry’s with-
drawal of pentaBDE and octabromo-
diphenyl ether (octaBDE) from the market
by the end of 2004 will decrease environ-
mental output. However, continued moni-
toring of environmental and human levels is
needed to measure exposures originating
from pentaBDE and octaBDE manufac-
tured before 2005 and to study potential
exposure to decaBDE, which will continue
to be manufactured.
Cleet’s second remark proposes the possi-
bility that current human PBDE levels have
reached a plateau. Because of the variability
in our data (Sjödin et al. (2004) and the
regionalized sampling, we believe such a con-
clusion may be premature. As Cleet men-
tions later in his letter, these studies may not
be representative of U.S. and European
populations. We did not claim that the sam-
pled pools are representative. To further con-
firm and track our preliminary observations
of human exposure to PBDEs, broader rep-
resentative studies have been proposed. 
Cleet’s third issue concerns comparabil-
ity of our data on BDE-47 with earlier
studies. We referenced several publications
regarding the similarity of our measured
levels to earlier findings. In a 1988 Illinois
study, human levels of BDE-47 were
reported to be 0.63 ng/g lipid, with a range
of < 0.4–24 ng/g lipid (Sjödin et al. 2001).
These Illinois levels can be contrasted to the
data from serum pools collected in the
southeastern United States, where we found
a range of < 1–6 ng/g lipid for the same
year [see Figure 1 in our paper (Sjödin et al.
2004)]. We also compared our BDE-47
levels to those in other studies: for example,
33 ng/g lipid in breast adipose tissue
(range 7–200 ng/g) collected in the late
1990s (She et al. 2002); 83 ng/g lipid in a
milk pool (n = 19) collected in 1997 in
New York (Betts 2002); 130 ng/g lipid in a
milk pool collected in 2000 in Austin,
Texas, and Denver, Colorado (Päpke et al.
2001); and 41 ng/g lipid in milk collected
in 2001 in Texas (Schecter et al. 2003).
These authors reported concentrations in
the same range as our study [e.g., Figure 1
in our paper (Sjödin et al. 2004)]. 
I appreciate Cleet’s clarification concern-
ing production stoppage of hexabromo-
biphenyl (hexaBB) in Europe. Also, Cleet’s
speculation about the differences in outcomes
in animal studies is potentially useful.
Although we did not study toxic effects of
PBDEs, we asserted the cited studies to be
examples of potential concern. We selected
the work of Eriksson and colleagues in this
regard, demonstrating observed effects in four
publications: Eriksson et al. (2001, 2002),
Viberg et al. (2002), and Sand et al. (2004).
The author declares he has no competing
financial interests.
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The Human Population:
Accepting Earth’s Limitations 
I thank Fowler and Hobbs for their letter
(2004) and their research (2003). The
view that a complexity of factors impacts
human population growth certainly
makes sense, and they have correctly
pointed out that scientifically organized
efforts to deal with human problems
must take account of manifold intercon-
nected events. Although it is necessary to
recognize and acknowledge the complexi-
ties inherent in cultural life and the nat-
ural world, it is equally important that a
dizzying array of variables not blind us to
certain scientific facts of biophysical real-
ity. Humankind is bound by such pre-
dominant facts because the workings of
the world exist independently of human
wishes and beliefs. 
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CorrespondenceWith this in mind, I thank Hopfenberg
for his article (2003) in which he provided
an elegant model that accounts for the
salient factors governing the dynamics of
global human population numbers.
According to his findings, the size of the
human population is determined primarily
by food availability.
The realization that these two points of
view differ—that there is complexity and
simplicity in the world we inhabit—does not
necessarily mean that one is correct and the
other incorrect. To the contrary, it could be
that each point of view is valid based on the
scope of observation.
It may be somehow not quite right to
agree with the entire idea of Hobbs and
Fowler (2004) that “human population size is
beyond human capacity to list, comprehend,
and synthesize” without noticing that the
same can be said regarding any observable
phenomenon. Reality is likely just as com-
plex as Hobbs and Fowler described; but it
is also clear from the research of Hopfenberg
(2003) and Hopfenberg and Pimentel
(2001) that the dynamics of human popula-
tion growth is no longer preternatural but
knowable, and that the population dynamics
of Homo sapiens is not essentially different
from the population dynamics of other
species in both the complexity and the sim-
plicity of the governing elements.
A comprehensive and objective approach
to human problems and human potentiality
must acknowledge that humankind is a part
of the biophysical world, not apart from it.
Although Hobbs and Fowler (2004) are cor-
rect to note the control human culture exer-
cises in “value systems, economics, politics
and religion” in taking account of what is
real, human and environmental health could
be increasingly at risk because humanity
denies scientific facts over which living
beings may not have control.
In light of the different sets of data pre-
sented by Fowler and Hobbs (2003) and by
Hopfenberg (2003), perhaps it is a misnomer
for Hobbs and Fowler (2004) to uniformly
describe the many, complicated ways human-
ity is changing the natural world as an
“unprecedented success.” Are particulate and
solid-waste pollution or the conversion of
biomass into human mass with resulting bio-
diversity loss examples of success? Perhaps the
economic success of the prevailing culture is
not sustainable and cannot be maintained
much longer. Unbridled economic globaliza-
tion, unrestricted increases in human con-
sumption of resources, and growing absolute
human population numbers are negatively
affecting Earth by degrading its fitness as a
habitat for humans and other species.
A point in human history may have
been reached when the scale and rate of
growth of economic expansion, the con-
sumption of natural resources, and the
increasing human population can be seen as
patently unsustainable. Understanding the
causes of and limits to humanity’s impact in
the world is a necessary step toward chang-
ing human production, consumption, and
population trends. Regardless of how long a
culture prizes growth and chooses to leave it
unchecked, surely it is not too late to accept
limits to growth of the human economy,
human consumption, and human numbers
worldwide by altering human behavior
accordingly.
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Conflicts of Interests:
Declarations for All
Concerning your editorial, “Embracing
Scrutiny,” in the October issue of EHP
[Environ Health Perspect 112:A788 (2004)],
the need for full disclosure of all potential
conflicts of interest by all coauthors con-
tributing to a publication in EHP is com-
mendable and obviously needed. Might I
take this one step further and suggest that all
reviewers of EHP manuscripts be required
to sign a form listing all of their potential
conflicts of interest.
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Daniel W. Nebert
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University of Cincinnati Medical Center
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Editor’s note: In our Instructions to Authors
(http://ehp.niehs.nih.gov/docs/admin/edpolicy.
html), we do require editors and reviewers to
disclose competing financial interests but are
not currently requiring a signed form. We are
considering taking that next step.
CORRECTIONS
In the letter by Storm and Mazor [Environ
Health Perspect 112:A862–A864 (2004)],
the title of Table 1 was incorrect; also, P1
and P2 were not exposed but were unex-
posed children tested in another study.
The corrected table is presented below.
At the time the October 2004 Forum
article “Farm Chore Checkup” [Environ
Health Perspect 112:A804 (2004)] went
to press, Anne Gadomski’s assessment of
the North American Guidelines for
Children’s Agricultural Tasks was sched-
uled for publication in the October 2004
issue of the American Journal of Public
Health (AJPH). However, publication of
the assessment in AJPH was delayed; a
new publication date has not been set.
EHP regrets the error.
Wasserman et al. detected errors in their
article “Water Arsenic Exposure and
Children’s Intellectual Function in
Araihazar, Bangladesh” [Environ Health
Perspect 112:1329–1333 (2004)]. In the
first paragraph of “Results” (p. 1331),
the values should be reversed to read
“On average, mothers and fathers
reported 2.9 and 3.7 years of education,
respectively.” In the second paragraph of
“Results” (“Exposure characteristics”), the
mean water As concentration should be
117.8 µg/L, not 117.8 µg/dL.
Also, on page 1332 in “As metabo-
lism,” the authors would like to clarify that
Chowdury et al. (2003) reported that only
the first reaction of the arsenic metabolic
pathway—the formation of MMA—is less
active in children than in adults.
Table 1. Child participants in VCS studies.
Exposed Unexposed
DD or DD or
ID Age ADD ID Age ADD
E9a 8– C 9 a 9–
E10a,b 6 X C10a 8–
E14a,b 12 X C14a 12 –
E17a 6 – C17a 5,7 –
P1b 8X
P2b 10 X
aChildren shown in Figure 1A (NYSDOH, unpublished
data; Schreiber et al. 2002). bChildren shown in
Figure 1B: E10 and E14 were from Schreiber et al.
(2002); P1 and P2 were unexposed children examined
in an NYSDOH study (NYSDOH 2004).
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